Premium
P4–410: Steady–state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease are not affected by co–administration of memantine
Author(s) -
Shua-Haim Joshua R.,
Smith Juanita M.,
Lefevre Gilbert,
Frank Picard,
Sedek Greg,
Athalye Sandeep,
Pommier Francoise
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.2152
Subject(s) - rivastigmine , memantine , pharmacokinetics , concomitant , medicine , pharmacology , regimen , metabolite , active metabolite , anesthesia , donepezil , dementia , disease
Background and objective: It has been shown that combining memantine and a cholinesterase inhibitor, which each affect different neurotransmitter systems, may offer further improvements in efficacy over either treatment alone in patients with Alzheimer’s disease. The present study was conducted to determine if memantine has any effects on the steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer’s disease.